DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
1. Formal Matters
A. In the response filed 10/19/26, Applicants submitted new claims. Therefore, the restriction dated 8/17/26 is hereby withdrawn.
B. Claims 23-27 are pending and are the subject of this Office Action.
2. Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
A. Claims 23, 24 and 27 are rejected under 35 U.S.C. 103 as being unpatentable over Brat et al. in view of Asfaha et al. (cited as NPL document 1 on the IDS filed 3/22/24).
The instant claims are essentially drawn to a method of screening C57BL/6 mice engineered to express the entire human IL8 gene locus and its regulatory elements and identifying potential therapeutic agents based on their ability to decrease, or lessen glioma growth.
Brat teaches the involvement of IL8 in glioma (for which glioblastoma is a species). See Title/Abstract. Brat also teaches (Introduction) that “[a] precise definition of the mechanisms by which IL-8 exerts its proangiogenic functions requires further study for the development of effective IL-8-targeted therapies”. Therefore, Brat provides motivation for screening for therapeutics modulation IL8.
Brat does not teach the use of PiggyBac-on Bac RP11-997L11, nor mice. However, Asfaha does teach the use of a human bacterial artificial chromosome (hBAC; RPL11-997L11) encompassing the entire IL-8 gene (first paragraph under “Materials and Methods”), which was purchased commercially and used to express IL8 in C57BL/6 mice.
Therefore, both the fact that IL8 is involved in the promotion of glioma, and that the claimed IL8 gene construct was commercially available at the time of the instant invention, it would have been obvious to have used the construct of Asfaha in the invention of Brat in order to express this gene for study of potential therapeutics.
Neither Brat nor Asfaha teach the specific gene integration position recited in claim 23. However, given the teachings in the prior art as discussed above, it would have been obvious to have determined an appropriate position for gene insertion.
B. Claims 23, 24 and 27 are rejected under 35 U.S.C. 103 as being unpatentable over Sharma et al. in view of Asfaha et al.
The instant claims are essentially drawn to a method of screening C57BL/6 mice engineered to express the entire human IL8 gene locus and its regulatory elements and identifying potential therapeutic agents based on their ability to decrease, or lessen glioma growth.
Sharma teaches the involvement of IL8 in glioma (for which glioblastoma is a species). See Title/Abstract. Sharma also teaches (Conclusion) “[i]n vitro targeting of IL-8/CXCR1/2 axes provided notable evidence of their therapeutic potential which may be bolstered with further in vivo studies”. Therefore, Sharma provides motivation for screening for therapeutics modulation IL8.
Sharma does not teach the use of PiggyBac-on Bac RP11-997L11, nor mice. However, Asfaha does teach the use of a human bacterial artificial chromosome (hBAC; RPL11-997L11) encompassing the entire IL-8 gene (first paragraph under “Materials and Methods”), which was purchased commercially and used to express IL8 in C57BL/6 mice.
Therefore, both the fact that IL8 is involved in the promotion of glioma, and that the claimed IL8 gene construct was commercially available at the time of the instant invention, it would have been obvious to have used the construct of Asfaha in the invention of Sharma in order to express this gene for study of potential therapeutics.
Neither Brat nor Asfaha teach the specific gene integration position recited in claim 23. However, given the teachings in the prior art as discussed above, it would have been obvious to have determined an appropriate position for gene insertion.
C. Claims 25 and 26 are rejected under 35 U.S.C. 103 as being unpatentable over either (1) Brat et al. or (2) Sharma et al., each in view of Asfaha et al., further in view of Carleton et al. (US 2021/0054063 – cited on the IDS filed 3/22/24)
The teachings of Brat, Sharma and Asfaha are seen above. None teach an anti-PD-1 antibody. However, Carleton teaches the use of a combination therapy for comprising anti-IL-8 and anti-PD-1 antibodies (i.e. inhibitors) in potential treatment of glioma/glioblastoma (paragraph [0125]).
3. Conclusion
No claim is allowable.
Advisory information
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ROBERT S LANDSMAN whose telephone number is 571-272-0888. The examiner can normally be reached M-F 8 AM – 6 PM (eastern).
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joanne Hama, can be reached at 571-272-2911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/ROBERT S LANDSMAN/Primary Examiner, Art Unit 1647